Pharmacovigilance is the safety net that operates after a medicine is approved. The work is reviewing adverse-event reports as they arrive, coding them and assessing causality, watching aggregate data for signals no single report would reveal, and writing the periodic safety updates regulators require. When a signal holds up, it changes a label, a treatment guideline, or occasionally withdraws a product entirely.

This is one of the most natural industry moves a pharmacist can make. You already have the pharmacology, the interaction knowledge, and a sense of what a plausible adverse reaction looks like — the judgement that separates a real signal from noise. Clinical experience also means you understand how a report was generated in the first place, which is exactly what someone arriving from a pure data background lacks.

In Ghana this is a licensed role, not just a job title. The Public Health Act 2012 requires every company holding a marketing authorisation to appoint a Qualified Person for Pharmacovigilance who is resident in the country — and a B. Pharmacy is explicitly one of the qualifying degrees. The FDA runs the recognised QPPV training, designation lasts three years, and renewal depends partly on staying in good standing with a professional body such as PSGH. Many people start as a back-up QPPV before taking the lead role.